Background:
Clinical benefit of Molnupiravir (MPV) in COVID-19 infected sub-populations is unclear.
Methods:
We used a matched cohort design emulating a target trial to analyze the VA COVID-19 Shared Resource database to determine the association of MPV with hospitalization or death within 30 days compared with untreated controls in previously uninfected non-hospitalized persons. Incidence of hospitalization/death and absolute risk difference (ARD) with 95% confidence intervals were calculated for the treated and untreated groups.
Results:
Among 1,459 matched pairs, the incidence of hospitalization/death was not different among MPV treated vs. untreated controls (48 vs. 44 cases; ARD [95% CI] 0.27 [-0.94,1.49]). No benefit was observed among those >60 or <60 years old (ARD 0.27 [-1.25,1.79] vs. -0.29 [-1.22,1.80]), those with specific comorbidities, or by vaccination status. A significant benefit was observed in asymptomatic but not in symptomatic persons (ARD -2.80 [-4.74,-0.87] vs. 1.12 [-0.31,2.55]). Kaplan-Meier curves did not show a significant reduction in proportion of persons who were hospitalized or died among those treated with MPV compared with untreated controls (logrank P=0.7).
Conclusions:
MPV was not associated with a significant reduction in hospitalization or death within 30 days of COVID-19 diagnosis overall. A subgroup of patients presenting without symptoms experienced a benefit.
INCIDENCE OF HOSPITALIZATION OR DEATH WITHIN 30 DAYS AND ABSOLUTE RISK DIFFERENCE AMONG PATIENTS WHO RECEIVED MOLNUPIRAVIR AND CONTROLS. RESULTS FOR THE MATCHED GROUPS.![]()